quarta-feira, 7 de outubro de 2026
PesquisarExplore
pt.VIA.NEWS
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· April 23, 2026

The Best Artificial Intelligence (AI) Growth Stocks on the Nasdaq That Wall Street Loves Right Now

View original at nasdaq.com
The Best Artificial Intelligence (AI) Growth Stocks on the Nasdaq That Wall Street Loves Right Now Key Points Wall Street analysts love these two artificial intelligence (AI) stocks…
Opening lines of the source · short snapshot — read the full document at the original

O que extraímos desta fonte

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • If you invested $1,000 in Nvidia on April 15, 2005, you'd have $1,241,433

    60% confidence

  • Some $4 trillion is projected to be spent on data centers in 2030 worldwide, up from $1 trillion in 2025

    60% confidence

  • Applied Digital is targeting $1 billion in net operating income (NOI) over the next five years

    60% confidence

  • If you invested $1,000 in Netflix on December 17, 2004, you'd have $502,837

    60% confidence

  • Stock Advisor's total average return is 977% compared to 200% for the S&P 500

    60% confidence

  • 100% of the 13 analysts that cover Applied Digital rate it a buy, with a median price target of $43 per share, suggesting 32% upside

    60% confidence

  • Interest is high among hyperscalers for all of these new facilities

    60% confidence

  • Roughly 93% of the 70 analysts who cover Nvidia say it is a buy with a median price target of $267.50, suggesting about 33% upside

    60% confidence

Data points we hold from this source

S&P 500 · return200 percent
O que sabemos · a inteligência por trás desta página
Ao vivo do substrato
O que estamos a ver
Autumn 2026 Biopharma Catalyst Season: Late-Breaking Data, FDA Milestones and the Rise of AI-Designed Drugs
Late-September and early-October 2026 conferences (EASD, EADV, IGCS) brought a cluster of positive late-breaking trial readouts. These covered obesity and metabolic disease (Novo Nordisk's CagriSema), immunology (Lilly's EBGLYSS, tulisokibart) and oncology (Rina-S, Agenus BOT+BAL). Ahead lie hard regulatory catalysts, led by the 14 Nov 2026 FDA PDUFA date for ivonescimab. At the same time, Insilico-style AI-designed drugs such as rentosertib are showing anti-aging signals. That points to AI-driven drug discovery moving from concept toward clinical validation. Unrelated tech and regulatory items (Tesla Cybercab probe, xAI litigation, OpenAI agent incident) and the speculative QAIAx claims are peripheral to this story.
A nossa leitura dos dados ›
Sinais que acompanhamos
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Padrões que observamos ›
Onde as fontes divergem
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
Sinalizamos conflitos abertamente ›
Verificado recentemente
✓ Verificado com a fonte original
4,986
factos rastreados à sua fonte — e sinalizamos os que não se confirmam.
101 entidades acompanhadas4,986 factos verificados com a fonte5,362 documentos-fonte arquivados
Consulte estes dados → isubstrate.com
The Best Artificial Intelligence (AI) Growth Stocks on the Nasdaq That Wall Street Loves Right Now — Source | Via News | pt.VIA.NEWS